AIM: A multi-centred, open-labelled, phase 11 study containing 46 patients was conducted to evaluate the clinical benefit of gemcitabine (1,400 mg/m(2)) combined with 5-FU (3 g/m(2)) in a 48 h continuous infusion (CI). METHODS: Both drugs were administered on days 1, 8 and 15 of every 4 week cycle in chemotherapy-naïve patients with locally advanced unresectable metastatic pancreatic carcinoma. The minimum follow-up was 6 months. RESULTS: Clinical benefit response was the primary endpoint and this was achieved by 24.4% of the patients. Quality of life (QoL) improved in 16.6% of patients. Objective response was observed in 7% of the patients. The median progression-free survival (PFS) was 14.4 weeks and the median overall survival (OS) time was 22.7 weeks. One-year survival was 25%. The most frequent grade 3-4 toxicities were neutropenia (45%), mucositis (7.5%) and hyperbilirubinaemia (10.5%). CONCLUSIONS: This schedule was not superior in terms of clinical benefit, response rate, PFS and OS than standard gemcitabine treatment
AIM: A multi-centred, open-labelled, phase 11 study containing 46 patients was conducted to evaluate the clinical benefit of gemcitabine (1,400 mg/m(2)) combined with 5-FU (3 g/m(2)) in a 48 h continuous infusion (CI). METHODS: Both drugs were administered on days 1, 8 and 15 of every 4 week cycle in chemotherapy-naïve patients with locally advanced unresectable metastatic pancreatic carcinoma. The minimum follow-up was 6 months. RESULTS: Clinical benefit response was the primary endpoint and this was achieved by 24.4% of the patients. Quality of life (QoL) improved in 16.6% of patients. Objective response was observed in 7% of the patients. The median progression-free survival (PFS) was 14.4 weeks and the median overall survival (OS) time was 22.7 weeks. One-year survival was 25%. The most frequent grade 3-4 toxicities were neutropenia (45%), mucositis (7.5%) and hyperbilirubinaemia (10.5%). CONCLUSIONS: This schedule was not superior in terms of clinical benefit, response rate, PFS and OS than standard gemcitabine treatment
Authors: C Louvet; T André; P Hammel; F Selle; B Landi; S Cattan; M Fonck; M Flesch; P Colin; J Balosso; P Ruszniewski; A de Gramont Journal: Ann Oncol Date: 2001-05 Impact factor: 32.976
Authors: W Scheithauer; B Schüll; H Ulrich-Pur; K Schmid; M Raderer; K Haider; W Kwasny; D Depisch; B Schneeweiss; F Lang; G V Kornek Journal: Ann Oncol Date: 2003-01 Impact factor: 32.976
Authors: H Oettle; M Arning; U Pelzer; D Arnold; C Stroszczynski; J Langrehr; P Reitzig; M Kindler; J Herrenberger; R Musch; E W Korsten; D Huhn; H Riess Journal: Ann Oncol Date: 2000-10 Impact factor: 32.976
Authors: J E Kurtz; F Kohser; S Négrier; V Trillet-Lenoir; S Walter; J M Limacher; M Untereiner; L Kayitalire; D Jaeck; P Dufour Journal: Hepatogastroenterology Date: 2000 Sep-Oct
Authors: E Aranda; E Díaz-Rubio; A Cervantes; A Antón-Torres; A Carrato; T Massutí; J M Tabernero; J Sastre; A Trés; J Aparicio; J M López-Vega; I Barneto; J García-Conde Journal: Ann Oncol Date: 1998-07 Impact factor: 32.976
Authors: J Feliu; M P López Alvarez; M A Jaraiz; M Constenla; J M Vicent; J Belón; L López Gómez; J de Castro; J Dorta; M González Barón Journal: Cancer Date: 2000-10-15 Impact factor: 6.860
Authors: A Marantz; S Jovtis; E Almira; L Balbiani; J L Castilla; L Fein; D Lewi; G Pasccon; R Pinckevicius; G Uranga; M Abal; M Muiño; M Reale; S Agusto Journal: Semin Oncol Date: 2001-06 Impact factor: 4.929
Authors: S Cascinu; R R Silva; S Barni; R Labianca; L Frontini; E Piazza; G Pancera; P Giordani; L Giuliodori; M A Pessi; V Fusco; G Luporini; R Cellerino; G Catalano Journal: Br J Cancer Date: 1999-07 Impact factor: 7.640
Authors: Anteneh A Tesfaye; Hongkun Wang; Marion L Hartley; Aiwu Ruth He; Louis Weiner; Nina Gabelia; Lana Kapanadze; Muhammad Shezad; Jonathan R Brody; John L Marshall; Michael J Pishvaian Journal: J Pancreat Cancer Date: 2019-05-02